Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial

Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing

(2022) Alice Cho et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV

(2021) Daniele Armenia et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Sequencing DNA with nanopores: Troubles and biases

(2021) Clara Delahaye et al.   PLoS One

Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial)

(2020) Charlotte Charpentier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A quantitative approach for measuring the reservoir of latent HIV-1 proviruses

(2019) Katherine M. Bruner et al.   NATURE

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)

(2018) Véronique Joly et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Defective proviruses rapidly accumulate during acute HIV-1 infection

(2016) Katherine M Bruner et al.   NATURE MEDICINE

Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)

(2013) Charlotte Charpentier et al.   PLoS One

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

(2012) Slim Fourati et al.   AIDS

Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals

(2010) Slim Fourati et al.   AIDS